Local research. Human connections. WCR Miami Lakes (786) 483-7856
Back to study searchNCT06375759
Active, not recruitingNCT06375759ClinicalTrials.gov record

Mis S-S Bypass Versus Adhesion Lysis in PTS

Syringomyelia · Spinal Cord Injury

THE QUICK READ

What this study involves

The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.

Study type
Interventional
Phase
Not applicable
Age range
18 years - 80 years
Sex eligible
All sexes
Healthy volunteers
Not accepted
Participants
80 Actual

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

To determine whether A novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass results in better patient outcomes with improved quality of life and fewer complications compared to intradural adhesion lysis in individuals with posttraumatic Syringomyelia.

Read the full description

Recently, our team was the first to report in the Journal of Neurosurgery: Spine (JNSSPINE) a minimally invasive subarachnoid-subarachnoid cerebrospinal fluid bypass technique for the treatment of post-traumatic syringomyelia. This novel approach has attracted considerable international attention and achieved favorable clinical outcomes for the treatment of post-traumatic syringomyelia. To establish high-level evidence, participants with posttraumatic Syringomyelia will be randomized to either have A novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass or intradural adhesion Lysis. The participant will then return to the neurosurgeon's office at the following time points which are consistent with standard of care practice: 3-6, 12±2months. At these visits, the clinician will complete a physical exam and the participant will report on the prognosis of symptoms and complete questionnaires. A spine MRI will be performed 3-6, 12±2months after the surgery.

The multicenter design, target sample size, assessor masking, eligibility criteria, and outcome hierarchy described in this record were specified in the ethics-approved protocol before enrollment of the first participant. The initial public registry entry did not fully reflect the finalized protocol. The registry record was corrected on 2026-11, before database lock and before any unblinded between-group analysis, to align it with the prospectively approved protocol.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

  • History of traumatic spinal cord injury
  • Evidence of progressive neurological deficit and/or pain syndrome
  • MRI showing a syringomyelia due to spinal cord injury
  • Both myelography and MRI show extensive arachnopathy exceeding 2 spinal segments in length

Exclusion Criteria:

  • Chiari malformation
  • Myelomalacia
  • Subarachnoid cyst
  • Syringomyelia due to other spinal diseases (such as degenerative spinal disease)
  • Marked spinal kyphosis
Understand screening

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment
Random assignment
Masking
Single masked
A novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass

After dissections of the normal arachnoid mater at the cephalic and caudal sites, 2 tubes made of medical grade silicone (internal diameter 1.1 mm, external diameter 2.5 mm; Sophysa Systems Corp.) were inserted into the cephalic and caudal ends of the normal subarachnoid space.

The tubes were only inserted into the normal subarachnoid space, with the remaining portions running subcutaneously.

Procedure: A novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass

Intradural Adhesion Lysis

The dura is opened sharply, exposing the spinal cord. After microsurgical dissection adhesion, the dura is sewn closed with a dural graft.

Procedure: Intradural Adhesion Lysis

A novel minimally invasive Subarachnoid-Subarachnoid (S-S) Bypass PROCEDURE

After dissections of the normal dura mater at the cranial and caudal sites, a tunneling device (a passer) was used to create a subcutaneous tunnel. Two tubes made of medical grade silicone (internal diameter 1.1 mm, external diameter 2.5 mm; Sophysa Systems Corp.) were inserted into the cranial and caudal ends of the normal subarachnoid space.

Under the surgical microscope, the normal dura was incised bilaterally approximately 3 mm on either side of the midline at the cranial end. The arachnoid was opened, with the proximal ends of the drainage tubes inserted approximately 5 cm into the normal subarachnoid space, with the remaining portions running subcutaneously. No loosening operations were performed at the site of injury. The incisions were sutured layer by layer

Intradural Adhesion Lysis PROCEDURE

Intradural spinal cord Adhesion Lysis

Prepare your questions

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

The Number of Patients With Clinical Improvement

Time frame: 3-6, 12±2 months

Number of patients who experienced improvement in clinical or neurological symptoms-such as; sensory dysfunction (numbness, paresthesia, or sensory loss), neuropathic pain, motor weakness, gait impairment, bowel and bladder dysfunction, and spasticity.

Secondary measures

change of the volume of syrinx,

Time frame: 3-6, 12±2 months

defined as change in length, maximal cross-sectional diameter, or both.

Klekamp and Sammi syringomyelia scale

Time frame: 3-6, 12±2 months

for evaluating the spinal cord function, Each item is scored on a scale from 0 to 5, with 5 representing the best possible functional status.

modified Japanese Orthopaedic Association Scores (mJOA)

Time frame: 3-6, 12±2 months

Motor function, sensory, bladder function;for evaluating the spinal cord function;0-17, higher scores mean a better outcome

xuanwu syringomyelia scale

Time frame: 3-6, 12±2 months

for evaluating the spinal cord function, for evaluating the spinal cord function;0-18, higher scores mean a worse outcome

complication

Time frame: 3-6, 12±2 months

various complication, such as fever, csf fistula

ASIA score

Time frame: 3-6, 12±2 months

American Spinal Injury Association(ASIA) Score for evaluating the spinal cord function, degree of the spinal cord function, motor1-100, sensory 1-224, higher scores mean a better outcome

VAS score

Time frame: 3-6, 12±2 months

VAS Score for evaluating the degree of the pain, VAS 0-10, higher scores mean a worse outcome

No results are flagged as posted.

Review the complete result tables and limitations in the official record.

Open official results ↗

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

Fengzeng JianBeijing, Beijing Municipality, ChinaStatus unknown

Study team and timeline

Lead sponsor
Xuanwu Hospital, Beijing
Study start
Jun 25, 2025 Actual
Primary completion
Jun 25, 2027 Estimated
Study completion
Jun 25, 2027 Estimated
First posted
Apr 19, 2024 Actual
Last updated
Nov 10, 2026 Actual

Official study contacts

No central contact is listed. Check the locations and the official record.

Official study title

A Novel Minimally Invasive Subarachnoid-Subarachnoid (S-S) Bypass Versus Adhesion Lysis in Post-traumatic Syringomyelia

A HUMAN NEXT STEP

Ask Wellness Clinical Research

Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.

Please do not include medical records, diagnoses, medications, insurance numbers or other sensitive details. This form is for general questions, not urgent care.

Sending a question does not enroll you in a trial.

Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.

Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026